However, as less than 2% of NB patients have tumors with p53 mutations at the time of diagnosis53,54, this indicates that a large group of NB patients may benefit from MDM2i, and possibly in combination with CDK4/6i in some specific cases. This evidence concerns the gene CDK4 and neuroblastoma.